Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.53 USD
+0.02 (0.92%)
Updated May 10, 2024 01:54 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Innate Pharma SA Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 100 | 107 | 142 | 173 | 245 |
Receivables | 60 | 40 | 22 | 25 | 21 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 160 | 147 | 164 | 198 | 266 |
Net Property & Equipment | 7 | 9 | 12 | 13 | 13 |
Investments & Advances | 11 | 37 | 47 | 44 | 41 |
Other Non-Current Assets | 11 | 15 | 35 | 34 | 19 |
Deferred Charges | 10 | 9 | 6 | 8 | 1 |
Intangibles | 0 | 2 | 52 | 53 | 109 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 199 | 219 | 316 | 351 | 450 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 22 | 34 | 34 | 55 |
Current Portion Long-Term Debt | 10 | 2 | 36 | 2 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 19 | 24 | 16 | 79 |
Total Current Liabilities | 43 | 44 | 95 | 52 | 136 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 15 | 17 | 36 | 45 | 47 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 34 | 42 | 16 | 19 | 19 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 52 | 59 | 43 | 56 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 143 | 162 | 189 | 173 | 206 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 4 | 4 | 5 | 5 | 4 |
Capital Surplus | 416 | 400 | 444 | 425 | 414 |
Retained Earnings | -365 | -348 | -322 | -252 | -174 |
Other Equity | 1 | 1 | 1 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 56 | 57 | 127 | 178 | 244 |
Total Liabilities & Shareholder's Equity | 199 | 219 | 316 | 351 | 450 |
Total Common Equity | 56 | 57 | 127 | 178 | 244 |
Shares Outstanding | 80.80 | 80.20 | 79.30 | 78.90 | 76.50 |
Book Value Per Share | 0.70 | 0.71 | 1.60 | 2.26 | 3.18 |
Fiscal Year End for Innate Pharma SA Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 100 | -99,999 | 97 | -99,999 |
Receivables | NA | 60 | NA | 61 | NA |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 0 | NA | NA | NA |
Other Current Assets | NA | 0 | NA | NA | NA |
Total Current Assets | NA | 160 | NA | 158 | NA |
Net Property & Equipment | NA | 7 | NA | 8 | NA |
Investments & Advances | NA | 11 | NA | 39 | NA |
Other Non-Current Assets | NA | 11 | NA | 1 | NA |
Deferred Charges | NA | 10 | NA | 11 | NA |
Intangibles | NA | 0 | NA | 1 | NA |
Deposits & Other Assets | NA | 0 | NA | 0 | NA |
Total Assets | NA | 199 | NA | 217 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 18 | NA | 21 | NA |
Current Portion Long-Term Debt | NA | 10 | NA | 6 | NA |
Current Portion Capital Leases | NA | 0 | NA | NA | NA |
Accrued Expenses | NA | 0 | NA | NA | NA |
Income Taxes Payable | NA | 0 | NA | NA | NA |
Other Current Liabilities | NA | 15 | NA | 15 | NA |
Total Current Liabilities | NA | 43 | NA | 41 | NA |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 15 | NA | 17 | NA |
Convertible Debt | NA | 0 | NA | NA | NA |
Long-Term Debt | NA | 34 | NA | 39 | NA |
Non-Current Capital Leases | NA | 0 | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | 57 | NA | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | NA |
Total Liabilities | NA | 143 | NA | 154 | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 4 | NA | 4 | NA |
Capital Surplus | NA | 416 | NA | 416 | NA |
Retained Earnings | NA | -365 | NA | -358 | NA |
Other Equity | NA | 1 | NA | 1 | NA |
Treasury Stock | NA | 0 | NA | NA | NA |
Total Shareholder's Equity | NA | 56 | NA | 63 | NA |
Total Liabilities & Shareholder's Equity | NA | 199 | NA | 217 | NA |
Total Common Equity | 0 | 56 | 0 | 100,062 | 0 |
Shares Outstanding | 80.80 | 80.80 | 80.60 | 80.40 | 80.40 |
Book Value Per Share | 0.00 | 0.70 | 0.00 | 1,244.55 | 0.00 |